Coronavirus Disease 2019 Outcomes Among Recipients of <scp>Anti‐CD20</scp> Monoclonal Antibodies for <scp>Immune‐Mediated</scp> Diseases: A Comparative Cohort Study

Abstract

Patients who received anti-CD20 monoclonal antibodies for immune-mediated diseases prior to COVID-19 had higher mortality following COVID-19 than matched comparators, highlighting the urgent need to mitigate excess risks in recipients of anti-CD20 monoclonal antibodies during the ongoing pandemic.